Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising plans through debt or equity in the provided pages of the document. The management discusses ongoing capacity expansions and R&D investments but does not indicate plans for raising funds via debt or equity. They focus on operational improvements, product filings, and marketing expenditures, with no direct references to fundraising activities. Legal and market-related uncertainties, such as patent issues and litigation, are acknowledged but without linkage to fundraising strategies. Overall, based on the provided extract, no plan

Any current/future capex/capital investment/strategic investment?

The Goa manufacturing facility has been expanded; some minor bottlenecks and teething issues are being overcome with expected ramp-up to full rated capacity in the coming months. Certain additional capital expenditure related to warehousing is pending; this may be done either within the current year or the next year. Deferred tax provisioning related to capital expenditure is being monitored, with some room for adjustments depending on actual capitalization timelines. No specific new large-scale capex or strategic investment announcements were detailed; focus remains on optimizing existi

Future growth expectations in sales/revenue/volumes?

For FY2018, Unichem expects growth better than the market average, aiming to outpace overall industry growth (Page 16). Despite demonetization impacts in November-December 2016 causing some revenue loss (~7.5%), January 2017 showed a positive traction, indicating recovery (Page 14). Unichem aims for a double-digit growth rate on a year-to-date basis for FY2017 and anticipates continuing this momentum into FY2018 (Page 14). Domestic chronic segment, constituting about 62% of revenue, is showing better traction than acute segments (Page 3). Pillar brands demonstrate positive growth trends, suppo

Future growth expectations in earnings/operating earnings/profits/EPS?

The company aims to improve EBITDA margins beyond the current ~11.5%, targeting a rise to around 15% over 2-3 years through improvements in productivity and operational leverage. (Page 19) For FY2017, management expects EBITDA margins to improve sequentially with a positive trajectory continuing into FY2018. (Page 22) Domestic formulations growth is expected to rebound post demonetization effects, with more than double-digit growth anticipated for FY2018. (Page 15 & 22) The US subsidiary and other international businesses show strong growth, contributing positively to consolidated profits. (Pa

Current/ Expected Orderbook/ Pending Orders?

Unichem currently has around 17 pending ANDA (Abbreviated New Drug Applications) files in the US market. These pending filings cover products identified earlier, mostly normal generics with existing competition (20-30 approvals already). Market size per product is roughly USD 20 to 30 million at the manufacturing level, aggregating to around half a billion USD for all 17 products. Out of these, about 15 products have had a soft launch, with one launched fully in Q3. The company plans to launch 2-3 more products in upcoming quarters, depending on pricing and supply chain. Most pending products

Unichem LaboratoriesQ3 FY17Pharmaceuticals & Biotechnology

Unichem Laboratories Q3 FY17 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹498.75P/E: 29.5Market Cap: ₹3.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

For FY2018, Unichem expects growth better than the market average, aiming to outpace overall industry growth (Page 16).
Despite demonetization impacts in November-December 2016 causing some revenue loss (~7.5%), January 2017 showed a positive traction, indicating recovery (Page 14).
Unichem aims for a double-digit growth rate on a year-to-date basis for FY2017 and anticipates continuing this momentum into FY2018 (Page 14).
Domestic chronic segment, constituting about 62% of revenue, is showing better traction than acute segments (Page 3).
Pillar brands demonstrate positive growth trends, supporting overall revenue increases (Page 3).
OTC segment, especially with products like Unienzyme, is expected to contribute meaningfully to growth through strategic ad spend and brand building (Pages 4, 10).
International businesses, including US, UK, Brazil, and South Africa subsidiaries, continue to grow, contributing to consolidated revenue growth (Page 3).

Margin guidance

Category 2

The company aims to improve EBITDA margins beyond the current ~11.5%, targeting a rise to around 15% over 2-3 years through improvements in productivity and operational leverage. (Page 19)
For FY2017, management expects EBITDA margins to improve sequentially with a positive trajectory continuing into FY2018. (Page 22)
Domestic formulations growth is expected to rebound post demonetization effects, with more than double-digit growth anticipated for FY2018. (Page 15 & 22)
The US subsidiary and other international businesses show strong growth, contributing positively to consolidated profits. (Page 3)
R&D expenditure remains steady at ~4.5% of sales to support future product development and revenue growth. (Page 22)
Marketing expenses, especially in OTC products like Unienzyme, are expected to increase to scale operations, which may impact near-term margins but help long-term growth. (Page 4 & 22)
Overall, management targets consistent improvement in profits and EPS by leveraging operational efficiencies and market expansion. (Page 19 & 22)

See what Unichem Laboratories management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or future fundraising plans through debt or equity in the provided pages of the document.
The management discusses ongoing capacity expansions and R&D investments but does not indicate plans for raising funds via debt or equity.
They focus on operational improvements, product filings, and marketing expenditures, with no direct references to fundraising activities.
Legal and market-related uncertainties, such as patent issues and litigation, are acknowledged but without linkage to fundraising strategies.
Overall, based on the provided extract, no plans for new fundraising through debt or equity have been disclosed or discussed.

Order book

Unichem currently has around 17 pending ANDA (Abbreviated New Drug Applications) files in the US market.
These pending filings cover products identified earlier, mostly normal generics with existing competition (20-30 approvals already).
Market size per product is roughly USD 20 to 30 million at the manufacturing level, aggregating to around half a billion USD for all 17 products.
Out of these, about 15 products have had a soft launch, with one launched fully in Q3.
The company plans to launch 2-3 more products in upcoming quarters, depending on pricing and supply chain.
Most pending products (15 out of 17) are backward integrated.
No specific detailed orderbook numbers provided, focus is on product launches and regulatory approvals.

See what Unichem Laboratories management said on order book — free account, 30 seconds.

Capex plans

Yes

The Goa manufacturing facility has been expanded; some minor bottlenecks and teething issues are being overcome with expected ramp-up to full rated capacity in the coming months.
Certain additional capital expenditure related to warehousing is pending; this may be done either within the current year or the next year.
Deferred tax provisioning related to capital expenditure is being monitored, with some room for adjustments depending on actual capitalization timelines.
No specific new large-scale capex or strategic investment announcements were detailed; focus remains on optimizing existing facility expansion and associated costs.
The company is methodically managing marketing and R&D spends to balance growth and margins rather than engaging in heavy upfront investments.

Track Unichem Laboratories — get its next earnings analysis in your feed

How does Unichem Laboratories rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisUnichem Laboratories

Rev 3Mar 2

See where Unichem Laboratories sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Unichem Laboratories rank in Pharmaceuticals & Biotechnology?

Compare Unichem Laboratories against every Pharmaceuticals & Biotechnology company (Q3 FY17) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Unichem Laboratories's management said in earlier quarters

Earlier calls (3)

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules (Q2 FY27)
11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sotac Pharmaceuticals (Q2 FY27)
7,654.95 lakhs; Operating margin ≈ 10.68% for HY Sep 2026 . Key results statement takeaways from Sotac Pharmaceuticals Ltd's Q2 FY27 results statement — and how
Bio Medica Lab (Q2 FY27)
EBITDA for the quarter:** ₹510 lakhs, up 25% year-on-year (YoY). Key results statement takeaways from Bio Medica Laboratories Ltd's Q2 FY27 results statement —
Syncom Formulations (India) (Q2 FY27)
Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026):** ₹14,821.08 lakhs (Unaudited) . Key results statement takeaways from Syncom Formulations (India) Ltd's Q2 F

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →